Mylan may have overcharged taxpayers $1.27 billion for EpiPen

Mylan may have overcharged taxpayers $1.27 billion for EpiPen


Mylan classified its EpiPen as a generic drug rather than a brand-name drug under the rebate program, which resulted in the alleged extra payments in excess of $1 billion. Whichever formula yields the higher value determines the brand-name drug's basic rebate amount.



from Biotech News